Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
J2H-1702 in healthy female subjects
NCT06308874Phase 1Completed
- Sponsor
- J2H Biotech
- Start
- Jan 2023
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of J2H-1702 in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by J2H Biotech. Primary endpoints: Maximum Plasma Concentration at 48 hours and Maximum Pharmacodynamic Effect at 12 hours. Started Jan 2023; status: completed.
02
Drugs
J2H-1702
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06308874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06308874.